PRNewswire/ -- iLeukon Therapeutics, Inc., a San Diego-based clinical-stage biotechnology company developing next-generation mRNA-based immunotherapies, announced new clinical results from the ongoing ...

An international research team focused on aging reports that urolithin A at 1,000 mg per day shifted human immune profiles ...

CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced a ...

Data are being presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual MeetingSAN FRANCISCO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage ...

Why do immune cells that are supposed to eliminate viruses suddenly turn against our own body? There are instances where killer T cells—which are meant to precisely remove virus-infected ...

Although penile cancer represents less than 1% of male malignancies, it carries substantial physical and psychological burden ...

Urolithin A, a natural postbiotic known to trigger mitophagy, rejuvenated key immune cell functions in healthy middle-aged ...